PMID- 23197855
OWN - NLM
STAT- MEDLINE
DCOM- 20140227
LR  - 20211021
IS  - 2157-6564 (Print)
IS  - 2157-6580 (Electronic)
IS  - 2157-6564 (Linking)
VI  - 1
IP  - 6
DP  - 2012 Jun
TI  - Perivascular stem cells: a prospectively purified mesenchymal stem cell 
      population for bone tissue engineering.
PG  - 510-9
LID - 10.5966/sctm.2012-0002 [doi]
AB  - Adipose tissue is an ideal source of mesenchymal stem cells for bone tissue 
      engineering: it is largely dispensable and readily accessible with minimal 
      morbidity. However, the stromal vascular fraction (SVF) of adipose tissue is a 
      heterogeneous cell population, which leads to unreliable bone formation. In the 
      present study, we prospectively purified human perivascular stem cells (PSCs) 
      from adipose tissue and compared their bone-forming capacity with that of 
      traditionally derived SVF. PSCs are a population (sorted by 
      fluorescence-activated cell sorting) of pericytes (CD146+CD34-CD45-) and 
      adventitial cells (CD146-CD34+CD45-), each of which we have previously reported 
      to have properties of mesenchymal stem cells. Here, we found that PSCs underwent 
      osteogenic differentiation in vitro and formed bone after intramuscular 
      implantation without the need for predifferentiation. We next sought to optimize 
      PSCs for in vivo bone formation, adopting a demineralized bone matrix for 
      osteoinduction and tricalcium phosphate particle formulation for protein release. 
      Patient-matched, purified PSCs formed significantly more bone in comparison with 
      traditionally derived SVF by all parameters. Recombinant bone morphogenetic 
      protein 2 increased in vivo bone formation but with a massive adipogenic 
      response. In contrast, recombinant Nel-like molecule 1 (NELL-1; a novel 
      osteoinductive growth factor) selectively enhanced bone formation. These studies 
      suggest that adipose-derived human PSCs are a new cell source for future efforts 
      in skeletal regenerative medicine. Moreover, PSCs are a stem cell-based 
      therapeutic that is readily approvable by the U.S. Food and Drug Administration, 
      with potentially increased safety, purity, identity, potency, and efficacy. 
      Finally, NELL-1 is a candidate growth factor able to induce human PSC 
      osteogenesis.
FAU - James, Aaron W
AU  - James AW
AD  - Dental and Craniofacial Research Institute, University of California, Los 
      Angeles, USA. 900950-1579, USA.
FAU - Zara, Janette N
AU  - Zara JN
FAU - Zhang, Xinli
AU  - Zhang X
FAU - Askarinam, Asal
AU  - Askarinam A
FAU - Goyal, Raghav
AU  - Goyal R
FAU - Chiang, Michael
AU  - Chiang M
FAU - Yuan, Wei
AU  - Yuan W
FAU - Chang, Le
AU  - Chang L
FAU - Corselli, Mirko
AU  - Corselli M
FAU - Shen, Jia
AU  - Shen J
FAU - Pang, Shen
AU  - Pang S
FAU - Stoker, David
AU  - Stoker D
FAU - Wu, Ben
AU  - Wu B
FAU - Ting, Kang
AU  - Ting K
FAU - Peault, Bruno
AU  - Peault B
FAU - Soo, Chia
AU  - Soo C
LA  - eng
GR  - G1000816/MRC_/Medical Research Council/United Kingdom
GR  - T32 DE007296/DE/NIDCR NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20120611
PL  - England
TA  - Stem Cells Transl Med
JT  - Stem cells translational medicine
JID - 101578022
RN  - 0 (Antigens, CD34)
RN  - 0 (BMP2 protein, human)
RN  - 0 (Bone Morphogenetic Protein 2)
RN  - 0 (CD146 Antigen)
RN  - 0 (Calcium Phosphates)
RN  - 0 (Calcium-Binding Proteins)
RN  - 0 (MCAM protein, human)
RN  - 0 (NELL1 protein, human)
RN  - 0 (Nerve Tissue Proteins)
RN  - 0 (Recombinant Proteins)
RN  - EC 3.1.3.48 (Leukocyte Common Antigens)
RN  - EC 3.1.3.48 (PTPRC protein, human)
RN  - K4C08XP666 (tricalcium phosphate)
SB  - IM
MH  - Adipogenesis
MH  - Adipose Tissue, White/cytology/metabolism
MH  - Animals
MH  - Antigens, CD34/metabolism
MH  - Bone Matrix/metabolism
MH  - Bone Morphogenetic Protein 2/metabolism/pharmacology
MH  - *Bone Regeneration
MH  - CD146 Antigen/metabolism
MH  - Calcium Phosphates/metabolism
MH  - Calcium-Binding Proteins
MH  - Cell Culture Techniques
MH  - Flow Cytometry
MH  - Humans
MH  - Immunohistochemistry
MH  - Leukocyte Common Antigens/metabolism
MH  - Lipectomy
MH  - Male
MH  - Mesenchymal Stem Cells/*cytology/drug effects/metabolism
MH  - Mice
MH  - Mice, SCID
MH  - Nerve Tissue Proteins/metabolism
MH  - *Osteogenesis
MH  - Pericytes/*cytology/drug effects
MH  - Prospective Studies
MH  - Recombinant Proteins/metabolism/pharmacology
MH  - Regenerative Medicine/methods
MH  - Tissue Scaffolds
MH  - X-Ray Microtomography
PMC - PMC3659717
EDAT- 2012/12/01 06:00
MHDA- 2014/02/28 06:00
PMCR- 2013/06/01
CRDT- 2012/12/01 06:00
PHST- 2012/12/01 06:00 [entrez]
PHST- 2012/12/01 06:00 [pubmed]
PHST- 2014/02/28 06:00 [medline]
PHST- 2013/06/01 00:00 [pmc-release]
AID - sctm.2012-0002 [pii]
AID - 3781956 [pii]
AID - 10.5966/sctm.2012-0002 [doi]
PST - ppublish
SO  - Stem Cells Transl Med. 2012 Jun;1(6):510-9. doi: 10.5966/sctm.2012-0002. Epub 
      2012 Jun 11.